Phase I study of gemcitabine using a once every 2 weeks schedule.

Gemcitabine (2',2'-difluorodeoxycytidine) is a novel nucleoside analogue. As part of a series of studies to determine the maximum tolerated dose (MTD) of gemcitabine and the most appropriate schedule, a two-centre phase I study of gemcitabine was undertaken in patients with advanced refrac...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Vermorken, J. B., Guastalla, J. P., Hatty, S. R., Seitz, D. E., Tanis, B., McDaniels, C., Clavel, M. D.
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 1997
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2228173/
https://ncbi.nlm.nih.gov/pubmed/9400947
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars